Tags

Type your tag names separated by a space and hit enter

Efficacy of quetiapine in Parkinson's patients with psychosis.
J Clin Psychopharmacol. 2000 Feb; 20(1):54-60.JC

Abstract

Eleven patients with Parkinson's disease (PD) and acute psychosis received flexible doses of quetiapine between 25 and 300 mg/day based on clinical response and tolerance. Ten patients were receiving dopaminergic agents at baseline. Serial efficacy ratings (Brief Psychiatric Rating Scale, Clinical Global Impressions Scale), neuromuscular symptom assessments (Abnormal Involuntary Movement Scale, Simpson-Angus Scale, Unified Parkinson's Disease Rating Scale [UPDRS]), and adverse events monitoring were performed for up to 52 weeks. The patients had moderate hallucinations and/or delusions at baseline before the initiation of quetiapine. Nine of the 11 patients completed at least 12 weeks of treatment. Quetiapine was well tolerated in all but one patient, who became dizzy within the first week and withdrew from the study. Ten patients presented with moderate visual hallucinations. Quetiapine was markedly effective in controlling visual hallucinations in six of these patients. Symptoms of paranoia or delusions were less responsive to quetiapine. Four patients withdrew because of adverse events or comorbid medical problems, two withdrew because of a lack of efficacy, and five completed 52 weeks of treatment. The introduction of quetiapine did not exacerbate parkinsonian symptoms. Motor dysfunction, as measured by the UPDRS, revealed a slow, gradual worsening consistent with the progression of PD. Atypical antipsychotic medications such as quetiapine have a reduced likelihood of causing adverse drug-induced parkinsonism and therefore a possible role in treating psychotic symptoms in patients with PD.

Authors+Show Affiliations

Clinical Studies Limited, Philadelphia, Pennsylvania 19106, USA.No affiliation info available

Pub Type(s)

Case Reports
Clinical Trial
Clinical Trial, Phase III
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10653209

Citation

Targum, S D., and J L. Abbott. "Efficacy of Quetiapine in Parkinson's Patients With Psychosis." Journal of Clinical Psychopharmacology, vol. 20, no. 1, 2000, pp. 54-60.
Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol. 2000;20(1):54-60.
Targum, S. D., & Abbott, J. L. (2000). Efficacy of quetiapine in Parkinson's patients with psychosis. Journal of Clinical Psychopharmacology, 20(1), 54-60.
Targum SD, Abbott JL. Efficacy of Quetiapine in Parkinson's Patients With Psychosis. J Clin Psychopharmacol. 2000;20(1):54-60. PubMed PMID: 10653209.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of quetiapine in Parkinson's patients with psychosis. AU - Targum,S D, AU - Abbott,J L, PY - 2000/2/1/pubmed PY - 2000/3/18/medline PY - 2000/2/1/entrez SP - 54 EP - 60 JF - Journal of clinical psychopharmacology JO - J Clin Psychopharmacol VL - 20 IS - 1 N2 - Eleven patients with Parkinson's disease (PD) and acute psychosis received flexible doses of quetiapine between 25 and 300 mg/day based on clinical response and tolerance. Ten patients were receiving dopaminergic agents at baseline. Serial efficacy ratings (Brief Psychiatric Rating Scale, Clinical Global Impressions Scale), neuromuscular symptom assessments (Abnormal Involuntary Movement Scale, Simpson-Angus Scale, Unified Parkinson's Disease Rating Scale [UPDRS]), and adverse events monitoring were performed for up to 52 weeks. The patients had moderate hallucinations and/or delusions at baseline before the initiation of quetiapine. Nine of the 11 patients completed at least 12 weeks of treatment. Quetiapine was well tolerated in all but one patient, who became dizzy within the first week and withdrew from the study. Ten patients presented with moderate visual hallucinations. Quetiapine was markedly effective in controlling visual hallucinations in six of these patients. Symptoms of paranoia or delusions were less responsive to quetiapine. Four patients withdrew because of adverse events or comorbid medical problems, two withdrew because of a lack of efficacy, and five completed 52 weeks of treatment. The introduction of quetiapine did not exacerbate parkinsonian symptoms. Motor dysfunction, as measured by the UPDRS, revealed a slow, gradual worsening consistent with the progression of PD. Atypical antipsychotic medications such as quetiapine have a reduced likelihood of causing adverse drug-induced parkinsonism and therefore a possible role in treating psychotic symptoms in patients with PD. SN - 0271-0749 UR - https://www.unboundmedicine.com/medline/citation/10653209/Efficacy_of_quetiapine_in_Parkinson's_patients_with_psychosis_ L2 - https://doi.org/10.1097/00004714-200002000-00010 DB - PRIME DP - Unbound Medicine ER -